Characterizing immune and metabolic profiles in autism spectrum disorder through combined transcriptomics-metabonomics analysis.

Researchers studied genes and body chemistry in people with autism compared to those without. They found that people with autism had more active immune systems in their bodies and changes in brain communication chemicals. They also found differences in how the body processes certain nutrients and fats. These findings suggest autism involves both immune system problems and difficulties with brain connections working together.

This multi-omics study analyzed both gene expression and metabolite profiles in autism spectrum disorder (ASD) compared to typically developing individuals using existing databases. Researchers identified significant upregulation of immune-related genes (IL-1β, IFN-γ) indicating activated immune responses, while synaptic genes were downregulated suggesting impaired brain connectivity. Metabolic changes included increased phenylalanine and citrulline levels, along with altered lipid metabolism. Key regulatory factors RARA and NFKB2 were identified as potentially important modulators.

The parallel dysregulation of metabolic and transcriptomic pathways across different cohorts suggests common biological mechanisms underlying ASD, supporting integrated approaches to understanding the condition's complex biology.

Findings suggest ASD involves interconnected immune and metabolic dysfunction alongside synaptic impairments. This supports multi-target therapeutic approaches addressing immune modulation, metabolic support, and synaptic function rather than single-pathway interventions.

Study design not clearly specified, sample sizes not reported, and relies on existing database analysis rather than prospective data collection. Cross-sectional analysis cannot establish causality between identified changes and ASD development.

Autism Spectrum Disorders (ASD) encompass a range of complex neurodevelopmental conditions marked by difficulties in social communication, restricted interests, and repetitive behavior. In this study, we explore the potential interplay between metabolic and transcriptional alterations in ASD, aiming to uncover common biological disturbances that may contribute to the phenotype across cohorts. Transcriptional and metabolomic data for ASD and typically developing (TD) samples were sourced from the GEO database. After rigorous quality control and alignment of transcriptomic data using DESeq2 identified differentially expressed genes (DEGs).

For metabolomic data, MetaboAnalyst was used to find differentially expressed metabolites (DMs). Functional annotation was done using KEGG and GO, while Cytoscape facilitated network analysis. The analysis revealed significant upregulation of immune-related genes, including IL-1β and IFN-γ, indicating an activated immune response in ASD. Conversely, downregulation of synaptic genes suggests potential synaptic function impairments.

These findings highlight the influence of immune responses on neurodevelopment. Furthermore, notable metabolic changes were observed, with increases in metabolites like phenylalanine and citrulline, alongside alterations in lipid metabolism, aligning with dysregulated immune pathways and synaptic signaling. Key transcription factors, such as RARA and NFKB2, were also identified, emphasizing their critical roles in modulating these interconnected biological processes. The parallel findings of dysregulation of metabolic and transcriptomic pathways in ASD from distinct cohorts point towards intricate commonalities that contribute to its phenotype.

This multi-omics approach provides valuable insights and supports the development of precision medicine strategies. Future research should focus on longitudinal studies to explore these changes across developmental stages and environmental influences, offering a more comprehensive perspective on ASD management.